Onchilles Pharma Raises $7 Million Series A To Advance Drug Candidates To Activate Newly Discovered Broad-Acting Anticancer Pathway
Onchilles Pharma Raises $7 Million Series A To Advance Drug Candidates To Activate Newly Discovered Broad-Acting Anticancer Pathway
06/10/21, 11:09 AM
Location
san diegoRound Type
series a
Onchilles Pharma announced today a $7 Million Series A financing from LYZZ Capital and includes a $500,000 investment from the University of Chicago’s Startup Investment Fund. The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation. Research published in today’s issue of Cell is the first to describe this pathway where human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing non-cancer cells.
Company Info
Location
san diego, california, united states
Additional Info
Onchilles Pharma was founded on breakthrough research of a novel neutrophil pathway that when activated selectively and comprehensively kills cancer cells. Based on this research, the private biotech company is developing a pipeline of first-in-class drug candidates that have the potential to be broadly effective against a wide range of cancers. Onchilles is headquartered at the Alexandria GradLabs in San Diego. For more info, visit www.onchillespharma.com.